GlassScriptPhysician profile
Alireza Abidi
NPI 1215919477
$13,170.37
in general payments reported to CMS, 2019-2025
40 companies · $8,964 in 2025
The $8,964 reported for 2025 was more than what 90% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2022: $3,610 · 2023: $442 · 2025: $8,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,398 · Food and Beverage: $3,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,397.50 |
| Food and Beverage | $3,008.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,655.93 | 2023-2025 | Lynparza, Imfinzi |
| Intuitive Surgical, INC. | $3,243.16 | 2022 | |
| Glaxosmithkline, LLC. | $479.33 | 2025 | Zejula, Jemperli |
| Caris Mpi, INC. | $383.53 | 2025 | Mi Cancer Seek |
| Stryker Corporation | $376.26 | 2019-2022 | |
| Abbvie INC. | $236.47 | 2025 | |
| Genmab U.S., INC. | $229.29 | 2023-2025 | Epkinly |
| Merck Sharp & Dohme LLC | $140.73 | 2025 | Keytruda, Lynparza, Welireg |
| Dysis Medical, INC. | $138.20 | 2022-2023 | Dysis View, Dysis Ultra 2.0, Dysis V3 Digital Coploscope |
| Pfizer INC. | $124.62 | 2025 | |
| Tesaro, INC. | $118.43 | 2019 | |
| Janssen Biotech, INC. | $106.66 | 2025 | Tecvayli, Darzalex, Rybrevant |
| Eisai INC. | $86.41 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.45 | 2025 | |
| Jazz Pharmaceuticals INC. | $58.86 | 2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alireza Abidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.